U.S. Markets closed

Verastem promotes COO Robert Forrester to president

Verastem promoted Robert Forrester to President in addition to COO. Verastem is planning multiple clinical trials for 2013 across its programs targeting FAK and PI3K/mTOR. The current clinical plans include a midyear initiation of a potentially pivotal trial in mesothelioma for lead FAK inhibitor, VS-6063.